A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano, Alicia Danforth, Gerhard Gründer, Natalie Gukasyan, Friederike Holze, Benjamin Kelmendi, Michael Koslowski, Stephen Ross, Karina Sergi, Jordan Sloshower, Lukasz Smigielski, Dea Siggaard Stenbæk, Brandon Weiss, Max Wolff, David B. Yaden, Anna Owen, Scott T Aaronson, K. Clint Allen, Frederick S. Barrett, Michael P. Bogenschutz, Robin Carhart-Harris, Terence H. W. Ching, Alan K. Davis, Albert Garcia‐romeu, Roland R. Griffiths, Charles S. Grob, Keith G. Heinzerling, Peter S. Hendricks, David Horton, Matthew W. Johnson, Stéphanie Knatz Peck, Matthias E. Liechti, Lea J. Mertens, Francisco Moreno, Sandeep M. Nayak, Christopher R. Nicholas, Katrin H. Preller, Nathalie M. Rieser, Franz X. Vollenweider, Mary E. Yaden
Psychedelic Medicine January 20, 2025 DOI: 10.1089/psymed.2024.0019 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Reflexive thematic analysis Peer reviewed |
|---|---|
| Population | Psilocybin study materials from healthy and therapeutic populations |
| Topics | Psilocybin |
| Keywords | Field mathematics |
| Citations | 9 |
| Key points | Psychoeducation documents from psilocybin studies commonly emphasize biological and physical safety, psychological safety, setting, and expectancies, with biological and psychological safety prioritized across all sites. |
Abstract
Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for personal and family history of potential contraindications, and psychoeducational preparation with psychological support. Research settings typically provide psychoeducation to participants verbally and in writing (e.g., informed consent), and such documents and conversations can provide safety-related information—but may also introduce a wide range of expectancies. Such expectancies might involve the specific character of the acute subjective effects of psychedelics, possible side effects, and anticipated outcomes.
Methods: To better understand the content of this psychoeducation, we gathered study materials from many psilocybin studies conducted in the past two decades in healthy and therapeutic populations. We conducted a reflexive thematic analysis to better understand these documents.
Results: While these documents varied substantially between studies, we identified themes intended to lower levels of risk and optimize therapeutic effects from psychedelic treatments. The most frequently coded themes related to (1) biological and physical safety, (2) psychological safety and well-being, (3) aspects of setting, and (4) potential for expectancies. Prioritizing biological and psychological safety was evident in the materials from all sites. Furthermore, we identify potential contributors to expectancy unrelated to safety and suggest that these extrapharmacological elements be studied systematically in future research. Conclusions : Ideally, future research should strive to maximize safety while attempting to minimize extraneous expectancies.
Comparable studies
Other qualitative studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression enrolled in an open-label trial of psilocybin | 2017 | Qualitative study | n = 20 |
| Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis Adults aged 22 to 69 with clinically elevated anxiety associated with a cancer diagnosis | 2017 | Qualitative study | n = 13 |
| Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts Participants who completed a psilocybin-facilitated smoking cessation pilot study | 2018 | Qualitative follow-up study using semi-structured interviews and thematic analysis | n = 12 |
| Response of cluster headache to psilocybin and LSD Cluster headache patients who used psilocybin or LSD | 2006 | Qualitative study | n = 53 |
| Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress Adult participants with clinically elevated anxiety associated with a cancer diagnosis | 2017 | Qualitative study using interpretative phenomenological analysis | n = 13 |
Citations in the library
Cited by 8
- Key competencies for psychedelic treatment in real-world mental health care settings. General Hospital Psychiatry 2025
- Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis. AJOB empirical bioethics July 16, 2025
- Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings. Scientific Reports July 21, 2025
- Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland. The International Journal of Neuropsychopharmacology June 2, 2026
- Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings. International Journal of Methods in Psychiatric Research June 1, 2026
and 3 more in the library
Cites 78
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 73 more in the library